<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220907055908N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-09-18</date_registration>
      <primary_sponsor>Semnan University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the anti-inflammatory effect of colchicine in patients undergoing coronary artery bypass graft</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the anti-inflammatory effect of colchicine in patients undergoing coronary artery bypass graft (CABG) in Semnan kosar hospital in 1401: A randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-10-12</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65772</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Given that in this study, matching is going to be done based on gender and age group, and we want the number of participants in the intervention and control groups to be balanced as much as possible, so the randomization Stratified permuted block randomization method is used in this study. The age range of patients is 30 to 80 years. Therefore, patients are divided into two groups, 30-55 years old (younger) and 56-80 years old (older), based on the cut-off point in the middle of this range (55 years). According to the above-mentioned gender and age grouping, eligible patients are classified into 4 stratums:
Younger men, older men, younger women, older women
Considering that the study is of parallel type and two groups (parallel), the allocation of eligible patients (according to the defined entry and exit criteria) to the intervention and comparison groups is done separately in each of the above-mentioned strata. The two intervention and comparison groups should be matched in terms of age group and gender.
The sample size in each group is 45 people (90 people in total). We use blocks of four with numbers 1 to 6 as follows (in each block, a means the intervention group and b means the comparison group):
1-aabb
2-abba
3-abab
4-baba
5-baab
6-bbaa
By choosing the numbers using the table of random numbers based on the numbers one to six, select the above blocks in order and from left to right, the eligible people of each stratum in the order of entering the study and after obtaining informed consent to one of the two groups a or We attribute b. This selection is made 22 times and the first 88 eligible people are assigned to the groups.
For the last two people, we use a tap or a line to complete the sample list of 90 people and complete the balance, Blinding description: Both groups receive atorvastatin. Therefore, this drug does not require blinding. Regarding colchicine, a placebo will be used. That is, colchicine is given to the intervention group, and a placebo (instead of colchicine and completely similar to it in terms of appearance) is given to the control group. The drugs (or placebos) are placed in coded packages and are available to the researcher in the clinic. The researcher gives each patient a package (containing medicine or placebo), and the package delivery is based on the code specified for each participant (from the first to the ninety). The patients and the researcher will not be aware of the content of the package. Only the collaborator of the project (who is responsible for concealment management and also has the randomization list) is aware of the list and codes, which at the end of the study and after the analysis (or in (in case of emergency) can reveal the code.</study_design>
      <phase>3</phase>
      <hc_freetext>Coronary Artery Disease.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After conducting an interview and taking history and medical and medical records, 6 cc of blood was taken from the patient and after centrifugation and serum separation, it was kept at -70 degrees Celsius. 45 patients receive daily colchicine (1 mg daily) plus atorvastatin 80 mg daily from 3 days before surgery to 4 days after surgery. On the 8th day of the study, blood is taken from the patients again and the desired factors including CBC, serum CRP and interleukin 6 are measured by ELISA method and according to the kit's instruction. Intervention 2: Control group: 45 patients receive only atorvastatin 80 mg daily from 3 days before surgery to 4 days after surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyedeh Zahra Banihashemian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Semnan, Basij Boulevard, Semnan University of Medical Sciences</address>
        <city>Semnan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3514799442</zip>
        <telephone>+98 23 3345 1336</telephone>
        <email>seyedehzahra.banihashemian@gmail.com</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ahmad Nouri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Basij Boulevard, Semnan University of Medical Sciences</address>
        <city>Semnan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3514799442</zip>
        <telephone>+98 23 3345 1336</telephone>
        <email>ahmadnouri@semums.ac.ir</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>patients over 30 years old and under 80 years old
patients  needing CABG surgery
Informed consent</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>patients should have contraindications to colchicine or atorvastatin
patients with a history of severe liver diseases
patients who have creatinine clearance less than 50.
patients with a history of atrial fibrillation or atrial flutter or 2nd and 3rd-degree heart block
patients with autoimmune diseases or a history of taking immunosuppressive drugs in the last 1 month
patients with heart failure Ejection Fraction &lt; 35%
patients with a history of muscle conflicts
patients of taking fibrate drugs
patients with leukopenia or active infection
patients with acute coronary syndrome</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I25.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Atherosclerotic heart disease of native coronary artery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After conducting an interview and taking history and medical and medical records, 6 cc of blood was taken from the patient and after centrifugation and serum separation, it was kept at -70 degrees Celsius. 45 patients receive daily colchicine (1 mg daily) plus atorvastatin 80 mg daily from 3 days before surgery to 4 days after surgery. On the 8th day of the study, blood is taken from the patients again and the desired factors including CBC, serum CRP and interleukin 6 are measured by ELISA method and according to the kit's instruction.</i_keyword>
      <i_keyword>Control group: 45 patients receive only atorvastatin 80 mg daily from 3 days before surgery to 4 days after surgery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Interleukin 6. Timepoint: Before and after the intervention. Method of measurement: ELISA method.</prim_outcome>
      <prim_outcome>CRP. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometry.</prim_outcome>
      <prim_outcome>LDH. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometry.</prim_outcome>
      <prim_outcome>ESR. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometry.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>AF rhythm occurrence. Timepoint: Before and after the intervention. Method of measurement: Electrocardiogram(¬ECG).</sec_outcome>
      <sec_outcome>Gastrointestinal side effects (nausea, heartache, diarrhea and vomiting). Timepoint: after the intervention. Method of measurement: Examination.</sec_outcome>
      <sec_outcome>Death. Timepoint: after the intervention. Method of measurement: Examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Semnan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-08-29</approval_date>
        <contact_name>Ethics Committee of Semnan University of Medical Sciences</contact_name>
        <contact_address>Semnan, Basij Boulevard, Semnan University of Medical Sciences Semnan Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
